BRCA2 and prostate carcinoma: This could be of interest in setting testing criteria in these populations and may be due to a higher prevalence of aggressive prostate cancer in these populations and/or to higher Gleason scores in these populations that are known to be associated with germline BRCA2 pathogenic variants.19,20